Solventum Corporation (SOLV) Stock: Price, Forecast & Analyst Target
Solventum Corporation (SOLV) — MoonshotScore 66/100 (Strong band), calculated Nov 18, 2026. Price $85.80 (-0.79%), as of the Nov 19, 2026 trading session; market cap $14.6B.
Educational signal · not a buy or sell recommendation · How to read this
Solventum Corporation · SOLV · NYSE · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-13: Solventum sells wound care, surgical, dental, health information, and filtration solutions rather than functioning as a narrow medical instrument manufacturer. Its case rests on whether resilient demand across that portfolio can become durable cash generation after advance orders unwind and separation costs recede.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Solventum (SOLV)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a strained balance sheet and a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Full; Growth Durability: Flat; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- Altman Z 1.83 · Piotroski F 6
- ROE 3.2% · ROA 2.1% · current ratio 1.03
Holding back: balance-sheet strain
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 69 | Strong | |
| 70 | Strong | |
| 69 | Strong | |
| 69 | Strong | |
| 66 | Strong | |
| 66 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $85.80 | |
| Change on the day | -0.79% | |
| 52-week range | $62.38–$94.16 | |
| Market capitalisation | $14.6B | — |
| Price / earnings (trailing) | 96.70 | |
| Shares traded on the day | 786.5K | |
| Beta (volatility vs the S&P 500) | 0.75 |
Why Solventum scores 66
Share price, last 12 months +25.5%
$71.79 $90.08
What the price assumes
102.8% a year of free-cash-flow growth for ten years is what a $15.33B market value ( snapshot) asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $2.00M. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 11 of the last 11 reports (2024–2026); the stock still fell the next session after 5 of those beats. Average first-session move: 4.3% either way.
- -4.0%May ’24
- +8.4%Aug ’24
- -2.3%Nov ’24
- -5.1%Feb ’25
- +7.2%May ’25
- +1.1%Aug ’25
- +5.7%Nov ’25
- -1.2%Feb ’26
- +5.3%May ’26
- -5.7%Aug ’26
- +1.2%Nov ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | In line | +1.2% | — | |
| Beat | Beat | -5.7% | -3.0% | |
| Beat | Beat | +5.3% | +11.4% | |
| Beat | Beat | -1.2% | -5.7% | |
| Beat | Beat | +5.7% | +11.1% | |
| Beat | Beat | +1.1% | +0.9% | |
| Beat | Beat | +7.2% | +11.4% | |
| Beat | Beat | -5.1% | -9.9% | |
| Beat | Beat | -2.3% | -8.4% | |
| Beat | Beat | +8.4% | +5.3% | |
| Beat | Beat | -4.0% | -7.3% |
Beating the estimate has not been enough: the stock fell after 5 of the last 11 beats. The bar it has to clear is the whisper number, not the published one.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “supply agreement”, “erp-related advanced”, “regulatory approval” — none of them came up in Q2 FY2026.
- Getting louder: “margin expansion” (3 → 9 mentions), “operating margin” (3 → 7 mentions), “gross margins” (2 → 5 mentions).
- Gone quiet: “shareholder value”, “erp cutovers”, “health care”, “acquisition strategy” — regular themes last call, absent this time.
The tone held steady from one call to the next; what changed is the subject matter, not the confidence.
Our track record on this stock
Since the score went from 57 to 66 while the share price moved -6.0% through .
| Date | Band | 3 months | 6 months | Call |
|---|---|---|---|---|
| Fair → Strong | — | — | — |
The one band change we have recorded has not been graded yet; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 75% of 12 rate it a buy; the average target sits -1.1% from the price of $85.80.
- Last 90 days: 3 rating actions, every one a reaffirmation.
- Our signals: Strong band; strongest pillar Business Quality (82), weakest Financial Safety (25).
Here we and the crowd agree.
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Solventum (SOLV): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Four of these lenses read this company less favourably than the MoonshotScore does: Griffin-style lens, Englander-style lens, Klarman-style lens and Financial health lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Solventum (SOLV), and what does it report?
Short answer · as of
Hospitals, clinicians, dental practices, and other customers buy Solventum products ranging from wound dressings, sterilization assurance tools, stethoscopes, and electrodes to orthodontics, restorative materials, clinical documentation software, coding automation, filters, and membranes.
Research dated 2026-09-13.
Demand therefore reflects procedure activity, product usage, software adoption, and filtration needs rather than a uniform equipment cycle.
The reported product category represents a major share of sales but does not capture the whole economic mix described by the operating divisions. Health Information Systems brings software and workflow exposure alongside the physical consumables and devices found throughout Medsurg, Dental Solutions, and Purification and Filtration.
What do the latest results show for Solventum (SOLV)?
Research dated 2026-09-13.
The latest period produced the strongest revenue and gross profit in the displayed quarterly series. Operating profit and net income rebounded from the preceding period, while reported revenue and adjusted earnings again exceeded consensus, continuing a sustained run of positive surprises.
Management attributed part of that strength to advance orders and expects most of the associated sales and earnings benefit to reverse in the following period. That timing effect makes sequential growth a weak measure of underlying momentum until ordering normalizes.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $2.10B | $1.27B | $7.22 (diluted) |
| Dec 2025 | $2.00B | $63M | $0.36 (diluted) |
| Mar 2026 | $2.01B | $13M | $0.07 (diluted) |
| Jun 2026 | $2.21B | $92M | $0.53 (diluted) |
What are the financial strengths and risks for Solventum (SOLV)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Annual sales have remained within a narrow range while net income has varied sharply, including an unusually large contribution concentrated in a reported period. Recent profitability therefore looks stronger on trailing ratios than the surrounding quarterly earnings pattern alone would suggest.
Cash generation is the more immediate constraint. Operating cash flow recovered after a negative period, but the cash balance has declined across the reported window, debt substantially exceeds cash, and trailing free cash flow remains negative. Near term liquidity is tight rather than distressed: current assets barely cover current liabilities, liquid assets provide less coverage, and the quality screen remains comparatively favorable while the distress screen sits in an intermediate range.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 96.70 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Solventum (SOLV)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $8.25B · EPS 7.25 · 11 analysts.
Research dated 2026-09-13.
Advance order reversal is the immediate operating test: reported sales and earnings may fall even if customer demand has not deteriorated. The useful signals will be performance after that timing benefit leaves the comparison and whether results continue to clear expectations.
Cash conversion deserves equal attention. Management expects separation costs to decline and underlying cash generation to improve, so operating cash flow, capital spending, and the cash balance can test that claim. Product detail promised around the forthcoming investor event could also clarify where growth is expected across the portfolio.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Solventum compare with its peers?
Short answer
Solventum's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
The medical instruments and supplies label captures only part of Solventum. Its portfolio combines procedure linked consumables and devices with dental materials, clinical workflow software, coding automation, and filtration technologies, giving the business several distinct units of demand.
That breadth changes the comparison set. A medical products comparison addresses Medsurg and Dental Solutions, while software workflow and filtration economics require separate attention; treating the company as a uniform device supplier can misread changes in revenue mix and margins.
| Company | Price | Market value | Score |
|---|---|---|---|
| $242.61 Nov 18, 2026 | $34.1B | 95 5-pillar Nov 18, 2026 | |
| $404.02 Nov 18, 2026 | $28.1B | 92 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $132.25 Nov 19, 2026 | $13.0B | 81 5-pillar Nov 18, 2026 | |
| $74.52 Nov 19, 2026 | $35.8B | 80 5-pillar Nov 18, 2026 | |
| $14.85 Nov 19, 2026 | $12.4B | 77 5-pillar Nov 18, 2026 | |
| $140.34 Nov 19, 2026 | $8.90B | 77 5-pillar Nov 18, 2026 | |
| $176.59 Nov 19, 2026 | $10.3B | 74 5-pillar Nov 18, 2026 | |
| $170.29 Nov 19, 2026 | $10.9B | 71 5-pillar Nov 18, 2026 | |
| $15.12 Nov 19, 2026 | $10.3B | 71 5-pillar Nov 18, 2026 | |
| Solventum (SOLV) — this page | $85.80 | $14.6B | 66 |
| $163.40 Nov 19, 2026 | $6.48B | 61 5-pillar Nov 18, 2026 | |
| $25.39 Nov 19, 2026 | $13.1B | 57 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $35.00 – $113.00
- Consensus target
- $83.75
- Median target
- $97.50
- Revenue estimate
- $8.25B
- EPS estimate
- $7.25
Consensus record · Captured .
Measured against a quoted price of $85.80 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 1, 2026
- Transactions
- 4
- Identified insiders
- 2
- Purchases
- 0
- Sales
- 0
- Other transactions
- 4
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SOLV in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.13% | $29.96M | Added +91.0% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Solventum (SOLV)?
Common Questions About SOLV (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Solventum sell beyond medical instruments?
Solventum also sells dental and orthodontic materials, clinical documentation and coding software, voice recognition tools, filters, cartridges, purifiers, and specialized membranes. Those activities broaden its demand exposure beyond hospital equipment purchases.
Why could Solventum's advance order benefit reverse?
Management said customers pulled orders forward, boosting reported sales and earnings before the underlying demand would normally have appeared. Most of that timing benefit is expected to unwind in the following reporting period.
Can declining separation costs improve Solventum's cash generation?
Management expects cash generation to improve as separation costs recede, but the balance sheet has yet to demonstrate a durable recovery. Operating cash flow has been volatile, cash has declined, and debt remains well above cash.
Why does Solventum's outsized profit period complicate comparisons?
A large portion of annual net income was concentrated in an exceptional quarterly result, while surrounding periods reported much lower profit. Trailing margins therefore should be read alongside the quarterly sequence rather than treated as a steady operating run rate.
What is the SOLV stock price today?
The last price recorded for Solventum Corporation (SOLV), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the SOLV price target?
The analyst consensus price target for Solventum Corporation (SOLV), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 26 figures on this page — 19 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
